Matthew L. Posard

Director · 4 filings · Latest: Oct 1, 2026

HALOZYME THERAPEUTICS, INC.

Nautilus Biotechnology, Inc.

Ticker	Owner	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Filing
HALO	Matthew L. Posard	Director	Oct 1, 2026	Sale	$108.54	5,230	$567.7K	53,609	Oct 2 8:38 PM
HALO	Matthew L. Posard	Director	Sep 16, 2026	Sale	$107.74	18,996	$2.0M	58,839	Sep 17 9:19 PM
HALO	MATTHEW POSARD	—	Sep 16, 2026	Proposed Sale	$106.25	34,226	$3.6M	—	Sep 16 8:41 PM